



Policy Name: Short-Acting Opioid Post Limit Policy

Start Date: 4/1/19

Required Medical Information

- Members who have opioids prescribed for pain associated with a cancer diagnosis, terminal condition, or pain being managed through hospice or palliative care shall have access to the medication.
- Members who are opioid naïve shall not exceed thirty (30) morphine milligram equivalents (MMEs) total daily dose per day for a maximum total of twenty (20) tablets per the State of Rhode Island Opioid prescribing laws.
- The patient has tried and failed non pharmacologic therapy and non-opioid therapy to treat their pain AND has tried non pharmacologic therapy and/or non-opioid therapy in combination with a LOW DOSE opioid.
- The prescriber attests to understanding the findings of the CDC's Guideline for Prescribing Opioids for Chronic Pain (2016, 2017) which concluded that long term opioid therapy is associated with increased risk for serious harm (opioid use disorder, overdose, & death) in a dose-dependent manner: **≥ 50 MME** significantly increases risk for harm & indicates need to reassess; **≥ 90 MME** sharply increases risk for harm & requires justification of risk; **≥ 200 MME** is associated with Over Dose (OD) death
- The prescriber attests and acknowledges that the risk of serious harm is markedly increased with concurrent use of benzodiazepines (BZD) and other Central Nervous System (CNS) depressants.
- The prescriber attests that the patient has a prescription for or is in possession of naloxone.
- The prescriber attests that they have counseled the patient (and patient cohabitants, if available) on how to obtain and administer naloxone.

Renewal Criteria

- The original opioid dosing has been titrated down from the initial authorization or in the prescribers clinical opinion it is inappropriate to decrease the dose for this member.

Non-formulary

- The patient has tried and failed 3 formulary alternatives, or formulary alternatives would not be appropriate (contraindication, adverse effect, etc.).

Coverage Duration: All approvals x 1 year.



Policy Name: Short-Acting Opioid Post Limit Policy
Start Date: 4/1/19

Providers seeking dosages over the Post Quantity Limits below need to provide Neighborhood with documentation as to why such dosages are necessary.

Opioid Analgesics Quantity Limits Chart

The duration of 23 days is used for a 30-day fill period to allow time for refill processing. Limits are set up as quantity versus time edits.

If the quantities also exceed the initial quantity limit of the product recommended dose, 90 MME/day, 4 g/day of acetaminophen or aspirin, or 3200 mg/day of ibuprofen, then a rejection will occur. If the patient is requesting more than the initial quantity limit, then the claim will reject with a message indicating that quantity limits are exceeded.

	Authorization Limit (Post Limit QL)
Drug/Strength	<u>Number of Tablets per 25 days</u> that should be entered on the authorization: 200 MME/day, 4 g acetaminophen or aspirin, 3200 mg ibuprofen, or FDA Max Dose (whichever is less) Example: Oxycodone 30 mg 133 tablets per 30 days has a limit of 200 MME per day (Approvals above 200 MME/day are based on Clinical Judgment)
APAP/codeine soln 120-12 mg/5 mL	5000 mL (60 MME/day)
APAP/codeine susp 120-12 mg/5 mL	5000 mL (60 MME/day)
APAP/codeine tab 300/15 mg	400 tabs (30 MME/day)
APAP/codeine tab 300/30 mg	400 tabs (60 MME/day)
APAP/codeine tab 300/60 mg	400 tabs (120 MME/day)
APAP/cafeine/dihydrocodeine cap 320.5/30/16 mg	374 tabs (50 MME/day)
APAP/cafeine/dihydrocodeine tab 325/30/16 mg	369 tabs (49 MME/day)
ASA/cafeine/dihydrocodeine cap 356.4/30/16 mg	336 tabs (45 MME/day)
Benzhydrocodone/APAP 4.08 mg/325 mg	369 tabs (80 MME/day)
Benzhydrocodone/APAP 6.12 mg/325 mg	369 tabs (119 MME/day) APAP Limitation
Benzhydrocodone/APAP 8.16 mg/325 mg	369 tabs (159 MME/day)



Policy Name: Short-Acting Opioid Post Limit Policy

Start Date: 4/1/19

Codeine sulfate oral soln 30 mg/5 mL	840 mL (54 MME/day)
Codeine sulfate tab 15 mg	84 tabs (13.5 MME/day)
Codeine sulfate tab 30 mg	84 tabs (27 MME/day)
Codeine sulfate tab 60 mg	84 tabs (54 MME/day)
Hydrocodone/APAP tab 2.5/325 mg	369 tabs (31 MME/day)
Hydrocodone/APAP tab 5/300 mg	400 tabs (67 MME/day)
Hydrocodone/APAP tab 5/325 mg	369 tabs (62 MME/day)
Hydrocodone/APAP tab 7.5/300 mg	400 tabs (100 MME/day)
Hydrocodone/APAP tab 7.5/325 mg	369 tabs (92 MME/day)
Hydrocodone/APAP tab 10/300 mg	400 tabs (133 MME/day)
Hydrocodone/APAP tab 10/325 mg	369 tabs (123 MME/day)
Hydrocodone/APAP soln 7.5/325 mg/15 mL (5-217 mg/10 mL)	5500 mL (92 MME/day)
Hydrocodone/APAP elixir 10/300 mg/15 mL	6000 mL (133 MME/day)
Hydrocodone/APAP soln 10/325 mg/15 mL	5500 mL (123 MME/day)
Hydrocodone/ibuprofen tab 2.5/200 mg	480 tablets (40 MME/day)
Hydrocodone/ibuprofen tab 5/200 mg	480 tablets (80 MME/day)
Hydrocodone/ibuprofen tab 7.5/200 mg	480 tablets (125 MME/day)
Hydrocodone/ibuprofen tab 10/200 mg	480 tablets (160 MME/day)
Hydromorphone oral solution 5 mg/5 mL (1 mg/mL)	1,500 mL (200 MME/day)
Hydromorphone supp 3 mg	180 supps (72 MME/day)
Hydromorphone tab 2 mg	270 tabs (72 MME/day)
Hydromorphone tab 4 mg	270 tabs (144 MME/day)



Policy Name: Short-Acting Opioid Post Limit Policy

Start Date: 4/1/19

Hydromorphone tab 8 mg	188 tabs (200 MME/day)
Levorphanol tab 1 mg	180 tabs (66 MME/day)
Levorphanol tab 2 mg	180 tabs (132 MME/day)
Levorphanol tab 3 mg	180 tabs (198 MME/day)
Meperidine oral soln 50 mg/5 mL	120 mL (30 MME/day)
Meperidine tab 50 mg	24 tabs (30 MME/day)
Meperidine tab 100 mg	24 tabs (60 MME/day)
Morphine sulfate (conc) oral soln 20 mg/mL (100 mg/5 mL)	270 mL (180 MME/day)
Morphine sulfate oral soln 10 mg/5 mL	1350 mL (90 MME/day)
Morphine sulfate oral soln 20 mg/5 mL	1350 mL (180 MME/day)
Morphine sulfate supp 5 mg	270 supps (45 MME/day)
Morphine sulfate supp 10 mg	270 supps (90 MME/day)
Morphine sulfate supp 20 mg	270 supps (180 MME/day)
Morphine sulfate supp 30 mg	200 supps (200 MME/day)
Morphine sulfate tab 15 mg	270 tabs (135 MME/day)
Morphine sulfate tab 30 mg	200 tabs (200 MME/day)
Oxycodone cap 5 mg	270 caps (67.5 MME/day)
Oxycodone oral concentrate 100 mg/5 mL (20 mg/mL)	200 mL (200 MME/day)
Oxycodone soln 5 mg/5 mL	2700 mL (135 MME/day)
Oxaydo 5 mg	540 tabs (135 MME/day)
Oxaydo 7.5 mg	533 tabs (200 MME/day)
Oxycodone tab 5 mg	270 tabs (67.5 MME/day)



Policy Name: Short-Acting Opioid Post Limit Policy

Start Date: 4/1/19

Oxycodone tab 10 mg	270 tabs (135 MME/day)
Oxycodone tab 15 mg	267 tabs (200 MME/day)
Oxycodone tab 20 mg	200 tabs (200 MME/day)
Oxycodone tab 30 mg	133 tabs (200 MME/day)
Oxycodone/APAP soln 5/325 mg/5 mL	1800 mL (90 MME/day)
Oxycodone/APAP tab 2.5/300 mg	400 tabs (50 MME/day)
Oxycodone/APAP tab 2.5/325 mg	369 tabs (46 MME/day)
Oxycodone/APAP tab 5/300 mg	400 tabs (100 MME/day)
Oxycodone/APAP tab 5/325 mg	369 tabs (92 MME/day)
Oxycodone/APAP tab 7.5/300 mg	400 tabs (150 MME/day)
Oxycodone/APAP tab 7.5/325 mg	369 tabs (138 MME/day)
Oxycodone/APAP tab 10/300 mg	400 tabs (200 MME/day)
Oxycodone/APAP tab 10/325 mg	369 tabs (184 MME/day)
Oxycodone/ASA tab 4.8355/325 mg	369 tabs (89 MME/day)
Oxycodone/ibuprofen tab 5/400 mg	240 tabs (60 MME/day)
Oxymorphone tab 5 mg	360 tabs (180 MME/day)
Oxymorphone tab 10 mg	200 tabs (200 MME/day)
Pentazocine/naloxone 50/0.5 mg	324 tabs (200 MME/day)
RoxyBond 5 mg	540 tabs (135 MME/day)
RoxyBond 15 mg	267 tabs (200 MME/day)
RoxyBond 30 mg	133 tabs (200 MME/day)
Tapentadol oral soln 20mg/mL*	750 mL (200 MME/day)
Tapentadol tab 50 mg	210 tabs (140 MME/day)



Policy Name: Short-Acting Opioid Post Limit Policy

Start Date: 4/1/19

Tapentadol tab 75 mg	200 tabs (200 MME/day)
Tapentadol tab 100 mg	150 tabs (200 MME/day)
Tramadol 50 mg	240 tabs (40 MME/day)
Tramadol/APAP 37.5/325 mg	369 tabs (46 MME/day)